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mplantable Cardioverter-
efibrillator Therapy in
rrhythmogenic Right
entricular Cardiomyopathy*
Role for Genotyping in
ecision-Making?
homas Wichter, MD, FESC,
ünter Breithardt, MD, FESC, FACC
ünster, Germany
rrhythmogenic right ventricular cardiomyopathy (ARVC)
s a frequent cause of ventricular tachycardia (VT) and
udden death in apparently healthy adolescents and young
dults. In this issue of the Journal, Hodgkinson et al. (1)
eport on the role of implantable cardioverter-defibrillators
ICDs) in an autosomal form of familial ARVC in which a
p25 deoxyribonucleic acid haplotype (ARVD5) segregates
ith disease. Despite substantial efforts and extensive anal-
ses in large families from Newfoundland, the responsible gene
nd gene product have not yet been identified so far (2).
See page 400
he authors studied 11 families and stratified 367 sub-
ects to high-risk (n  197), low-risk (n  92), and
ndeterminate-risk (n  78) groups. They compared the
ortality in 48 high-risk subjects after ICD implantation
ith that in a matched historical control group of 58
igh-risk subjects who were alive at the same age at which
he ICD subjects received the device. In this high-risk
roup of subjects with ARVD5, male patients were at a
ignificantly greater risk of death when compared with
emales (odds ratio 5.1). The five-year mortality rate for
ales with an ICD was 0% compared with 28% in matched
ontrols. In the same five-year period, ICD therapies for any
T occurred in 70% and for VT 240 beats/min (poten-
ially life-threatening) in 30% of patients, irrespective of the
ndication for ICD implantation (primary or secondary
revention). The authors conclude that the unknown mu-
ation at the ARVD5 locus on chromosome 3p25 results in
igh mortality and that ICD therapy guided by risk strati-
cation, including genetic haplotyping, results in a signifi-
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Department of Cardiology and Angiology, Hospital of the University of
ünster, Münster, Germany. This work was supported by grants from the Europeani
ommission (QLG-CT-2000-01091), Brussels, Belgium, and the Deutsche For-
chungsgemeinschaft (SFB 556, project C4), Bonn, Germany.ant improvement of survival in male patients of this ARVC
opulation (1).
FFICACY OF ICD THERAPY IN PATIENTS WITH ARVC
n the present study by Hodgkinson et al. (1), the 78%
ppropriate ICD discharge rate during follow-up is remark-
bly similar to that reported in previous studies. Table 1
ummarizes the main results of initial preliminary reports
3–5) and recent studies in larger patient populations
1,6–8) with ARVC after implantation of an ICD system.
owever, when compared with the study by Wichter et al.
7), the follow-up period after ICD implantation is much
horter (mean 80 vs. 31 months), thus explaining the
ifferences in the rates of overall mortality and complications.
A unique and first-time feature of the present study is the
omparison of an ICD-treated group of patients with a
atched historical control group of similar risk profile
ithin a genetically homogeneous ARVD5 population.
espite this advantage, there are several limitations to the
tudy concept, which were addressed by the authors. Apart
rom a possible selection bias in the ICD group and the
etrospective analysis of clinical data in the historical control
roup, the median follow-up periods in ICD patients and
ontrol subjects differed significantly in male (2.6 vs. 9.5
ears) and female (0.7 vs. 28.8 years) patients, thus ques-
ioning some of the conclusions drawn from the follow-up
nalyses in the present study.
However, the reported 28% five-year total mortality
eduction in male patients with an ICD compared with
amilial controls has excellent correlation with the estimated
enefit of ICD therapy on survival reported in previous
tudies (5–7). Furthermore, the time to first ICD discharge
or VT 240 beats/min was similar to the time of death in
he control group. Therefore, the results from the present
tudy confirm the concept of “hypothetical death,” which
alculates the benefit of ICD therapy on survival by the
ifference between total mortality and the occurrence of
otentially lethal VT 240 beats/min, terminated by the
CD (7). In contrast to the findings in males, the results for
omen were not statistically significant, thus supporting the
linical observation that disease expression and long-term
rognosis in ARVC is less malignant in women.
Compared with previous series, most patients (73%) in
he study by Hodgkinson et al. (1) received the ICD for
rimary prevention of sudden death. The decision for ICD
mplantation was made on the basis of clinical risk stratifi-
ation and genetic haplotyping. Interestingly, the results
ndicate that the high rate of appropriate ICD discharges for
T is independent of the indication for ICD implantation
primary or secondary prevention), thus supporting previous
reliminary information (6,8) on the potential benefit of
CD implantation for primary prevention of sudden death
n ARVC patients considered to be at high risk. However,
n the general ARVC population, the criteria for optimal
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Editorial Comment Feburary 1, 2005:409–11election of patients who benefit from ICD implantation for
rimary prevention remain to be defined.
ENETIC BACKGROUND OF ARVC
pproximately 30% to 50% of index patients with ARVC
ave a familial background indicating a genetic origin of the
isease. However, because of incomplete diagnostic and
enetic work-up of family members, the proportion of
amilial cases of ARVC is probably underestimated.
In the autosomal-recessive Naxos disease, a syndromic
orm of ARVC with palmoplantar keratoderma and woolly
air, mutations in the JUP gene on chromosome 17q21,
ncoding the desmosomal protein plakoglobin, were iden-
ified. In the more frequent nonsyndromic autosomal-
ominant forms of ARVC, disease-causing mutations have
een identified in only three of nine chromosomal loci
etected (9,10). In ARVD2, mutations in the RYR2 gene
n chromosome 1q42-43, encoding for the human cardiac
yanodine receptor (calcium release channel protein), were
eported in the Veneto region of Italy. In ARVC8, muta-
ions in the DSP gene on chromosome 6p24, encoding for
he desmosomal protein desmoplakin, were identified. Very
ecently, mutations in the PKP2 gene on chromosome
2p11 (ARVC9) encoding for the desmosomal arm repeat
rotein plakophilin-2 were identified (10).
According to these findings, familial ARVC currently is
onsidered a disease of the desmosome, whereas familial
ypertrophic cardiomyopathy is regarded a disease of the
arcomere, and familial dilative cardiomyopathy is consid-
red a disease of the cytoskeleton.
ENOTYPE-PHENOTYPE
ORRELATIONS IN PATIENTS WITH ARVC
amilial ARVC is a genetically heterogeneous disorder with
ncomplete penetrance and variable phenotypic expression.
his variable expression results in significant difficulties in
he correct phenotyping of family members of index pa-
ients. Given the sometimes subtle and borderline clinical
ndings in early stages or mild forms of the disease, these
iagnostic limitations have hampered the identification of
able 1. Studies on ICD Therapy in ARVC
Author Year
Pts
(n)
Study
Type
Males
(%)
Follow-Up
(Months)
P
reithardt et al. (3) 1994 18 SC 72 17  11
ink et al. (4) 1997 12 SC 58 22  13
avernier et al. (5) 2001 9 SC 89 32  24
orrado et al. (6) 2003 132 MC 70 39  25
ichter et al. (7) 2004 60 SC 82 80  43
ougin et al. (8) 2004 42 MC 52 42  26
odgkinson et al. (1) 2005 48 MC 63 31
Five-year cumulative frequency for first appropriate ICD discharge.
ICD  implantable cardioverter-defibrillator; MC  multicenter study; NR  nhromosomal loci and affected genes by methods using minkage analysis and the candidate gene approach. As a
esult, the number of genotyped subjects with ARVC
eported in previous studies is very small.
However, it has become clear that in familial ARVC,
here is not only genetic (within chromosomal loci) but also
llelic (within affected genes) heterogeneity. Gerull et al.
10) recently reported 25 different heterozygous mutations
mostly stop signals) in the PKP2 gene on chromosome
2p11 (ARVD9) in 32 of 120 (27%) unrelated index
atients with ARVC. The gene encodes plakophilin-2, an
ssential arm repeat protein of the cardiac desmosome. The
uthors found a significant variability in disease penetrance
nd phenotypic expression, indicating that not only different
enes and gene products (proteins) but also different muta-
ions within an affected gene may be important. Moreover,
ven within families, in which all affected members carry the
ame genetic mutation, the clinical manifestation, disease
xpression, and long-term prognosis may differ significantly,
hus emphasizing the role of confounding environmental
actors and gene-gene interrelations (modifier genes). This
esults in a complex genetic situation similar to hypertrophic
ardiomyopathy, in which many of the mutations are
rivate, thus only present in a given family.
For these reasons, the findings of Hodgkinson et al. (1) in an
pparently genetically homogeneous population haplotyped to
RVD5 may not be transferable to the overall ARVC popu-
ation with different genetic backgrounds (between or within
enetic loci). In addition, because the gene responsible for
RVD5 has not yet been identified, the extent and the
onsequences of genetic heterogeneity within the 11 families
eported in the present study remain unknown.
Therefore, the clinical usefulness of genetic screening in
RVC for the purpose of risk stratification, assessment of
rognosis, and clinical decision making, also with regard to
CD implantation, remains questionable. At the present
ime, apart from the insights to disease mechanisms and
athophysiology, the main advantage of genotyping patients
ith ARVC is the potential to identify genetically affected
elatives of a diagnosed index patient at a subclinical and/or
symptomatic stage. An early identification of asymptom-
tic mutation carriers would offer the opportunity to provide
ary
ntion
)
Mortality
Overall
(%)
Appropriate
ICD Therapy
(%)
Life-Saving
ICD Therapy
(%)
Complications
(%)
0 0 50 NR NR
0 8 67 50 33
0 0 78 44 NR
2 3 48 24 14
7 13 68 40 45
0 2 78 NR 14
3 0 70* 30 6
orted; Pts  patients; SC  single-center study.Prim
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uring long-term follow-up.
UTURE OUTLOOK
n the future, a more detailed knowledge and understanding
f genotype-phenotype relationships in large populations of
atients with ARVC may ultimately result in the develop-
ent of genotype-specific treatment strategies (or even gene
herapy), based either on the pathophysiologic background
r on the prognostic implications of the underlying genetic
utation. Initial steps toward such a goal have been
eported in the long QT syndrome and other diseases. In
RVC, however, there is still a long way to go.
eprint requests and correspondence to: Priv.-Doz. Dr. med.
homas Wichter, Medizinische Klinik und Poliklinik C, Univer-
itätsklinikum Münster, D-48129 Münster, Germany. E-mail:
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